DAWN - Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $2.22B
- Beta
- -1.75
- 52-Week Range
- 5.635-21.53
- CEO
- Jeremy Bender
- Employees
- 181
- IPO Date
- May 27, 2021
- Exchange
- NASDAQ
DAWN Options Snapshot
Options pricing data for DAWN is refreshed daily after the close. When listed contracts exist, this page surfaces the latest at-the-money implied volatility, max pain strike, dealer gamma exposure (GEX), and 25-delta skew. Listed contracts and live snapshots appear once the options chain has been published by the exchange for the most recent session.
What This Page Covers
The DAWN overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.